Please use this identifier to cite or link to this item:
Title: Long-term Inhaled Nitric Oxide Plus Phosphodiesterase 5 Inhibitors for Severe Pulmonary Hypertension
Authors: Pérez-Peñate, Gregorio Miguel 
Juliá-Serdà, Gabriel
Ojeda-Betancort, Nazario
García-Quintana, Antonio
Pulido-Duque, Juan
Rodríguez Pérez, Aurelio Eduardo 
Cabrera-Navarro, Pedro 
Gómez-Sánchez, Miguel Angel
UNESCO Clasification: 32 Ciencias médicas
3205 Medicina interna
Keywords: Pulmonary hypertension
Nitric oxide
Phosphodiesterase 5 Inhibitors
Cyclic GMP
Issue Date: 2008
Journal: Journal of Heart and Lung Transplantation 
Abstract: Background: Inhaled nitric oxide (iNO) is a potent pulmonary vasodilator, but therapeutic experience in patients with severe pulmonary hypertension is scarce. Methods: Eleven patients with severe pulmonary hypertension, 6 due to pulmonary arterial hypertension and 4 due to chronic thromboembolic disease, were selected for iNO therapy. A phosphodiesterase type 5 inhibitor (PDE5i) was added in cases of clinical worsening. In this study we evaluate the clinical effectiveness and safety of long-term treatment with iNO either alone or combined with a PDE5i. Results: After 1 month of iNO administration, improvements were observed in World Health Organization functional class, Borg scale (p = 0.003), brain natriuretic peptide levels (p = 0.002) and 6-minute walk test (p = 0.003). After 6 months of treatment, 7 patients had clinical deterioration that was reversed upon adding a PDE5i. One of these patients died in Month 8 and another underwent pulmonary transplantation in Month 9. The clinical condition of the remaining 9 patients was unchanged after 1 year. A second right catheterization showed improvement in mean pulmonary arterial pressure (66 +/- 15 mm Hg to 56 +/- 18 mm Hg; p = 0.01), pulmonary vascular resistance (1,234 +/- 380 dyn/s/cm(5) to 911 +/- 410 dyn/s/cm(5); p = 0.008) and cardiac index (2.0 +/- 0.4 liters/min/m(2) to 2.5 +/- 0.4 liters/min/m(2); p = 0.04). There was no significant increase in methemoglobin, no worsening of pulmonary function and no sudden withdrawal syndrome. Conclusions: We suggest that iNO therapy alone or in combination with a PDE5i could be a therapeutic alternative for severe pulmonary hypertension.
ISSN: 1053-2498
DOI: 10.1016/j.healun.2008.08.007
Source: Journal of Heart and Lung Transplantation[ISSN 1053-2498],v. 27(12), p. 1326-1332 (Octubre 2008)
Appears in Collections:Artículos
Show full item record

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.